| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
–Induced Myofilament Protein Phosphorylation Contributes to Myofilament Dysfunction in Experimental Congestive Heart FailureFrom the Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois at Chicago.
Correspondence to Dr Pieter P. de Tombe, PhD, University of Illinois at Chicago, Department of Physiology and Biophysics, 835 S Wolcott (M/C 901), Chicago, IL 60612. E-mail pdetombe{at}uic.edu
It is becoming clear that upregulated protein kinase C (PKC) signaling plays a role in reduced ventricular myofilament contractility observed in congestive heart failure. However, data are scant regarding which PKC isozymes are involved. There is evidence that PKC-
may be of particular importance. Here, we examined PKC-
quantity, activity, and signaling to myofilaments in chronically remodeled myocytes obtained from rats in either early heart failure or end-stage congestive heart failure. Immunoblotting revealed that PKC-
expression and activation was unaltered in early heart failure but increased in end-stage congestive heart failure. Left ventricular myocytes were isolated by mechanical homogenization, Triton-skinned, and attached to micropipettes that projected from a force transducer and motor. Myofilament function was characterized by an active force–[Ca2+] relation to obtain Ca2+-saturated maximal force (Fmax) and myofilament Ca2+ sensitivity (indexed by EC50) before and after incubation with PKC-
, protein phosphatase type 1 (PP1), or PP2a. PKC-
treatment induced a 30% decline in Fmax and 55% increase in the EC50 in control cells but had no impact on myofilament function in failing cells. PP1-mediated dephosphorylation increased Fmax (15%) and decreased EC50 (
20%) in failing myofilaments but had no effect in control cells. PP2a-dependent dephosphorylation had no effect on myofilament function in either group. Lastly, PP1 dephosphorylation restored myofilament function in control cells hyperphosphorylated with PKC-
. Collectively, our results suggest that in end-stage congestive heart failure, the myofilament proteins exist in a hyperphosphorylated state attributable, in part, to increased activity and signaling of PKC-
.
Key Words: heart failure protein kinase C-
myofilament proteins protein phosphatase type 1 phosphorylation
This article has been cited by other articles:
![]() |
C. Hidalgo, B. Hudson, J. Bogomolovas, Y. Zhu, B. Anderson, M. Greaser, S. Labeit, and H. Granzier PKC Phosphorylation of Titin's PEVK Element: A Novel and Conserved Pathway for Modulating Myocardial Stiffness Circ. Res., September 25, 2009; 105(7): 631 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Varian, A. Kijtawornrat, S. C. Gupta, C. A.A. Torres, M. M. Monasky, N. Hiranandani, D. A. Delfin, J. A. Rafael-Fortney, M. Periasamy, R. L. Hamlin, et al. Impairment of Diastolic Function by Lack of Frequency-Dependent Myofilament Desensitizationin Rabbit Right Ventricular Hypertrophy Circ Heart Fail, September 1, 2009; 2(5): 472 - 481. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, X. Chen, S. M. MacDonnell, E. G. Kranias, J. N. Lorenz, M. Leitges, S. R. Houser, and J. D. Molkentin Protein Kinase C{alpha}, but Not PKC{beta} or PKC{gamma}, Regulates Contractility and Heart Failure Susceptibility: Implications for Ruboxistaurin as a Novel Therapeutic Approach Circ. Res., July 17, 2009; 105(2): 194 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Duncker, N. M. Boontje, D. Merkus, A. Versteilen, J. Krysiak, G. Mearini, A. El-Armouche, V. J. de Beer, J. M.J. Lamers, L. Carrier, et al. Prevention of Myofilament Dysfunction by {beta}-Blocker Therapy in Postinfarct Remodeling Circ Heart Fail, May 1, 2009; 2(3): 233 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Palaniyandi, L. Sun, J. C. B. Ferreira, and D. Mochly-Rosen Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res, May 1, 2009; 82(2): 229 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. van Dijk, D. Dooijes, C. dos Remedios, M. Michels, J. M.J. Lamers, S. Winegrad, S. Schlossarek, L. Carrier, F. J. ten Cate, G. J.M. Stienen, et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction Circulation, March 24, 2009; 119(11): 1473 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. A. Mou, C. Reboul, L. Andre, A. Lacampagne, and O. Cazorla Late exercise training improves non-uniformity of transmural myocardial function in rats with ischaemic heart failure Cardiovasc Res, February 15, 2009; 81(3): 555 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Molnar, A. Borbely, D. Czuriga, S. M. Ivetta, S. Szilagyi, Z. Hertelendi, E. T. Pasztor, A. Balogh, Z. Galajda, T. Szerafin, et al. Protein Kinase C Contributes to the Maintenance of Contractile Force in Human Ventricular Cardiomyocytes J. Biol. Chem., January 9, 2009; 284(2): 1031 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Solaro Multiplex Kinase Signaling Modifies Cardiac Function at the Level of Sarcomeric Proteins J. Biol. Chem., October 3, 2008; 283(40): 26829 - 26833. [Full Text] [PDF] |
||||
![]() |
N. Hamdani, V. Kooij, S. van Dijk, D. Merkus, W. J. Paulus, C. d. Remedios, D. J. Duncker, G. J.M. Stienen, and J. van der Velden Sarcomeric dysfunction in heart failure Cardiovasc Res, March 1, 2008; 77(4): 649 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Hanft, F. S. Korte, and K. S. McDonald Cardiac function and modulation of sarcomeric function by length Cardiovasc Res, March 1, 2008; 77(4): 627 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hambleton, A. York, M. A. Sargent, R. A. Kaiser, J. N. Lorenz, J. Robbins, and J. D. Molkentin Inducible and myocyte-specific inhibition of PKC{alpha} enhances cardiac contractility and protects against infarction-induced heart failure Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3768 - H3771. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |